Bixiang Zhang

Title: Bixiang Zhang: Innovator in Hepatocellular Carcinoma Research

Introduction

Bixiang Zhang is a prominent inventor based in Wuhan, China. He has made significant contributions to the field of medical research, particularly in the study of hepatocellular carcinoma (HCC) and its bone metastasis. His innovative methods have the potential to advance the understanding and treatment of this aggressive form of cancer.

Latest Patents

Bixiang Zhang holds a patent for "Methods for establishing animal model of hepatocellular carcinoma bone metastasis." This patent outlines a comprehensive method for creating an animal model that simulates the bone metastasis of HCC. The process involves establishing 97H and LM3 cell clones with stable expression of firefly luciferase, allowing HCC cells to form bone metastasis in nude mice through intratibial injection, and reproducing HCC bone metastasis via intracardiac injection of tumor cells. The method also includes isolating a sub-population of tumor cells that specifically targets bone metastasis.

Career Highlights

Throughout his career, Bixiang Zhang has focused on developing innovative techniques to study cancer metastasis. His work with highly metastatic HCC cell lines, such as 97H and LM3, has provided valuable insights into the mechanisms of cancer spread. He has conducted his research under stringent conditions, ensuring the welfare of the BALB/cA-nu mice used in his studies.

Collaborations

Bixiang Zhang has collaborated with notable colleagues, including Rui Hou and Yuwei Wang. Their combined expertise has contributed to the advancement of research in the field of hepatocellular carcinoma.

Conclusion

Bixiang Zhang's innovative methods for establishing animal models of hepatocellular carcinoma bone metastasis represent a significant advancement in cancer research. His contributions are poised to enhance the understanding of HCC and improve therapeutic strategies for patients.